BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation

Stock Information for BioXcel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.